TRANSFORM: What the Lymphoma Trial Found

Changing the order of treatments, not adding one

CAR T-cell therapy already existed when TRANSFORM began. A person's own T cells are collected, engineered to recognise a marker called CD19, and given back. It was used when everything else had failed.

TRANSFORM did not test a new product. It tested moving an existing one earlier, ahead of the salvage chemotherapy and stem-cell transplant that had held second place for decades.

Who was eligible

184 adults aged 18 to 75 took part, at 47 sites in the United States, Europe and Japan.

All had large B-cell lymphoma that either never responded to first treatment or came back within 12 months of responding. That group does badly on the old pathway. All were well enough to be considered for a transplant.

92 were assigned to lisocabtagene maraleucel, a CAR T-cell product. 92 were assigned to standard care: three cycles of salvage chemotherapy, then high-dose chemotherapy and a transplant of their own stem cells, but only for those whose lymphoma responded.

The gap in event-free survival

Event-free survival counts the time until the treatment fails, the disease progresses, or the person dies.

The median was 10.1 months with CAR T-cell therapy (95% CI 6.1 months to not reached) and 2.3 months with standard care (95% CI 2.2 to 4.3). The stratified hazard ratio was 0.35 (95% CI 0.23 to 0.53; one-sided p<0.0001), or roughly a 65% lower risk of failure or death at any moment.

Why the comparison arm looks so poor

Two point three months is a startling figure until you understand what it counts.

On the standard pathway, salvage chemotherapy comes first and the transplant only happens if the lymphoma responds. Many people never get that far. Failing to reach the transplant counts as an event. So the comparison arm is not measuring how transplant performs. It is measuring how a whole pathway performs, including everyone who falls out of it early.

That is a fair test of what actually happens to patients. It is not a fair test of transplant itself.

Side effects, including one that surprised people

Severe neutropenia affected 80% of the CAR T group against 51% of the standard-care group. Prolonged low blood counts affected 43% against 3%.

The CAR T-specific problems were milder than expected. Grade 3 cytokine release syndrome occurred in 1 of 92 people. Grade 3 neurological events occurred in 4. There were no grade 4 or 5 events of either kind. There were no treatment-related deaths in the CAR T group; one person on standard care died of sepsis.

What this report cannot tell you yet

• This is a planned interim analysis with a median follow-up of 6.2 months. That is very short for judging a lymphoma treatment.
• The main measure was event-free survival, not overall survival. At this analysis, it does not show that people live longer.
• The trial was open-label, and people on standard care could cross over to CAR T therapy. That blurs later survival comparisons.
• It applies to early failure or relapse in people fit for transplant. Not to later relapses, and not to people who are less fit.

Questions about second-line lymphoma treatment

• Did my lymphoma fail to respond, or come back, and how long after treatment?
• Am I considered fit for a transplant, and does that change my options?
• How long does making a CAR T product take, and what happens in the meantime?
• What monitoring is needed in the weeks after CAR T cells are given?

Sources

This article was written from the sources below, which were checked on the source-check date shown above.

• Lancet: Lisocabtagene Maraleucel vs Standard of Care with Salvage Chemotherapy and Transplant in Large B-Cell Lymphoma (TRANSFORM) (primary)

How this article was prepared

Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.

Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.